In the COMPASS trial,(1,2) combined aspirin and rivaroxaban treatment reduced ischaemic events in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD). In the October issue of European Heart Journal – Cardiovascular Pharmacotherapy, Dr Würtz and co-workers from Denmark applied the COMPASS study criteria to patients undergoing coronary angiography (CAG) in Western Denmark (2004–2011). The authors concluded that in their broad CAG cohort, 15% were eligible for combined aspirin and rivaroxaban treatment. COMPASS-eligible patients had up to 2.5-fold higher rates of cardiovascular events than non-eligible patients. These data may indicate that this group of patients may benefit from additional preventive measures.
Our mission: To reduce the burden of cardiovascular disease.